Zhi Tong Cai Jing·2025-12-09 11:47Core Insights - Fosun Pharma has signed a licensing agreement with Pfizer for the exclusive development, use, production, and commercialization rights of the oral small molecule GLP-1 receptor agonist YP05002 and related products globally [1][2] - The agreement includes an upfront payment of $150 million and potential milestone payments of up to $350 million based on clinical and commercialization progress [1] Group 1 - YP05002 is an innovative GLP-1 receptor agonist developed by the company, aimed at treating type 2 diabetes, obesity, and related metabolic disorders [2] - The drug works by activating GLP-1 receptors to enhance insulin secretion, reduce glucagon secretion, slow gastric emptying, and suppress appetite, thereby aiding in weight management and metabolic health [2] - As of December 9, 2025, YP05002 is in Phase I clinical trials in Australia, indicating ongoing development in the metabolic disease treatment space [2] Group 2 - The licensing agreement reflects recognition of the company's innovative research and development capabilities by its partners [2] - This collaboration is expected to accelerate the clinical development and commercialization of the licensed product globally, potentially benefiting a larger patient population [2]